Cargando…

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives

STING (Stimulator of Interferon Genes) agonists have emerged as promising agents in the field of cancer immunotherapy, owing to their excellent capacity to activate the innate immune response and combat tumor-induced immunosuppression. This review provides a comprehensive exploration of the strategi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Cuiqing, Shao, Ni, Huang, Yanyu, Chen, Jifeng, Wang, Duo, Hu, Genwen, Zhang, Hong, Luo, Liangping, Xiao, Zeyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630661/ https://www.ncbi.nlm.nih.gov/pubmed/38024837 http://dx.doi.org/10.1016/j.mtbio.2023.100839

Ejemplares similares

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
por: Ma, Xiaocong, et al.
Publicado: (2023)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022)

Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect
por: Shen, Ming, et al.
Publicado: (2022)

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
por: Go, Eun-Jin, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
por: Wang, Bin, et al.
Publicado: (2022)

Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022)

STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments
por: Guerini, Danilo
Publicado: (2022)

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature
por: Yang, Yongqing, et al.
Publicado: (2023)

PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy
por: Xiao, Zeyu, et al.
Publicado: (2022)

Interference With Redox Homeostasis Through a G6PD-Targeting Self-Assembled Hydrogel for the Enhancement of Sonodynamic Therapy in Breast Cancer
por: Huang, Cuiqing, et al.
Publicado: (2022)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma
por: Boudreau, C. Elizabeth, et al.
Publicado: (2021)

Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy
por: Shae, Daniel, et al.
Publicado: (2019)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
por: Dane, Eric L., et al.
Publicado: (2022)

Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Diagnostic Performance of Perfusion Computed Tomography for Differentiating Lung Cancer from Benign Lesions: A Meta-Analysis
por: Huang, Cuiqing, et al.
Publicado: (2019)

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
por: Zheng, Juyan, et al.
Publicado: (2020)

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
por: Wang, Duo, et al.
Publicado: (2021)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

STING activation in cancer immunotherapy
por: Su, Ting, et al.
Publicado: (2019)

Anticancer Effect of STING Agonist-Encapsulated Liposomes on Breast Cancer
por: Zhang, Jibing, et al.
Publicado: (2023)

STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy
por: Zhou, Lei, et al.
Publicado: (2023)

Identification of MSA-2: An oral antitumor non-nucleotide STING agonist
por: Liu, Jianhua, et al.
Publicado: (2021)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity
por: McAndrews, Kathleen M., et al.
Publicado: (2021)

Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages?
por: Ohkuri, Takayuki, et al.
Publicado: (2017)

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
por: Jang, Su Chul, et al.
Publicado: (2021)

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer
por: Esteves, Ana M., et al.
Publicado: (2021)

Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
por: Zhang, Ziyuan, et al.
Publicado: (2022)

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy
por: Dong, Wenpei, et al.
Publicado: (2023)

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
por: Nakamura, Takashi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjo3ks9uprafmfo8t7s5vf9a1h